Merck KGaA Stock Crashes as Earnings Miss Expectations by 30%

Merck KGaA's stock price plummeted after the company released disappointing earnings, missing second-quarter earnings per share estimates by approximately 30%. The decline was attributed to tighter profit margins and a cautious fiscal outlook.

The pharmaceutical giant's guidance suggests more conservative expectations ahead as investors reassess what they're willing to pay for the stock. Analysts note that this sell-off is driven by the gap between Merck's valuation and its underlying profitability rather than broader sector weakness.

Merck's late-stage pipeline and breakthrough regulatory status in generalized anxiety disorder could still be meaningful positives, but future performance will hinge on clearing major clinical and regulatory hurdles. Any setbacks could force more dilution, spending cuts, or a rethink of the company's growth story.